A new, large randomized trial assessing the relative efficacy of common drug treatments for smoking cessation provides strong evidence for the combined use of nicotine patches and nicotine lozenges to promote long-term abstinence (level 1 [likely reliable] evidence). A total of 1,504 participants who had smoked ≥ 10 cigarettes/day for at least 6 months were randomized to 1 of 5 treatments involving bupropion, nicotine lozenges or nicotine patches alone, or in combination, with matched placebo groups for each intervention. Each participant also received 6 individual counseling sessions. Carbon monoxide-confirmed abstinence rates 6 months after quitting were 40.1% for nicotine patches plus lozenges, 34.4% for patches alone, 33.5% for lozenges alone, 33.2% for bupropion plus lozenges, 31.8% for bupropion alone, and 22.2% for placebo. Only the combination of nicotine patches and lozenges was statistically superior to placebo after adjustment for multiple comparisons. However, there were no statistically significant differences in direct comparisons between patch plus lozenge and any of the other treatments at 6 months (Arch Gen Psychiatry 2009 Nov;66(11):1253).